$RGC (Regencell Bioscience Holdings Limited) reported earnings on June 8, 2026. Revenue came in flat year over year, posting 0.0% growth compared to the same period a year ago. The stock is trading at $21.27 as of the report date, with a market cap of $10.37B.
The trailing P/E ratio registers at 0.0, which typically signals the company is not currently reporting positive trailing earnings on a GAAP basis — though the data block does not specify the accounting treatment. We do not have a verified EPS figure for this reporting period, so no earnings-per-share growth rate is available. Readers can check the live figures at acceinvestments.com/stocks/RGC.
Regencell operates in the Healthcare sector and focuses on bioscience research and development. The company carries no dividend yield at this time.
Recibe el resumen semanal de ACCE
Rentabilidad de los índices, repaso de las selecciones y los mayores cambios de puntuación, cada domingo. Sin relleno.
What it means
The ACCE score for $RGC currently sits at 34 out of 100. That places it in the lower tier of our scoring range, which factors in fundamentals, momentum, and other quantitative signals. A score of 34 reflects meaningful caution across those dimensions.
Flat revenue growth is a neutral data point on its own, but context matters. For a small-cap healthcare company at this stage, holding revenue steady can indicate stability in an otherwise volatile sector — or it can signal a lack of commercial traction. Without additional segment detail or management commentary, it is difficult to draw a firm conclusion either way.
We do not have guidance commentary from this earnings report, so there is no forward outlook from the company to reference here. Any forward P/E figures in the data block also register at 0.0, consistent with the absence of reliable forward earnings estimates.
The combination of a 34 ACCE score, flat revenue, and no visible earnings base makes $RGC a name that warrants close monitoring rather than a straightforward read. For the most current price, valuation metrics, and any updated guidance, visit acceinvestments.com/stocks/RGC.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
